The GLP1-US Blog

What You'll Find Here

The GLP-1 medication landscape changed dramatically between 2021 and 2026, and most consumer-facing information online has not kept up. Our blog publishes medically-reviewed, evidence-anchored articles written for adults in the US who are considering, starting, or already taking a GLP-1 receptor agonist for type 2 diabetes or chronic weight management.

Every article on this blog is written by a named author (see our Editorial Board) and reviewed for clinical accuracy by a US-licensed clinician (MD, PharmD, or RN) prior to publication. Our ranking methodology documents how we evaluate the providers and medications we cover.

Topics We Cover

• Drug-vs-drug comparisons — head-to-head looks at Ozempic vs Wegovy, Zepbound vs Saxenda, and the SURMOUNT-5 head-to-head trial data for tirzepatide vs semaglutide.
• Side-effect deep-dives — what's common, what's serious, what to expect during titration, and when to call your clinician. Based on FDA prescribing information and clinical-trial adverse-event data.
• Cost & access guides — how to get a prescription legitimately, what NovoCare and LillyDirect actually cost in 2026, when insurance covers the obesity indication, and how to avoid counterfeit products.
• How-to guides — step-by-step for getting tirzepatide via telehealth, switching between products, managing the empty-stomach protocol for oral Wegovy.
• Patient-experience content — protein and lean mass during rapid weight loss, what to expect week-by-week, how to talk to your clinician about long-term continuation.

Editorial Standards

Because GLP-1 medications are a Your Money or Your Life (YMYL) topic, we hold our blog content to the same standards we apply to hub-level pages: every clinical claim is cited to a primary source (FDA labeling, peer-reviewed trial publication, or authoritative clinical body), every article is reviewed by a named licensed clinician before publication, and pricing and approval-status content is re-audited quarterly. Read the full process on the Editorial Board page.

Latest Articles